Innovent is profitable at home. IBI363 decides its global story

The technology

Innovent is no longer a one-drug story. It has 20 marketed products, 13 of them on China's national reimbursement list, spanning cancer, obesity, cholesterol, eye disease and psoriasis. The anchors are sintilimab (TYVYT), a PD-1 antibody now approved for ten indications, and mazdutide, which Innovent calls the world's first approved glucagon/GLP-1 dual agonist for weight management and type 2 diabetes.

The pipeline value sits in three assets the company says have entered or will soon enter global phase 3 trials. IBI363 is a PD-1 antibody fused to an IL-2 arm biased toward the alpha receptor, meant to wake up immune cells in tumors that no longer respond to PD-1 drugs. Arcotatug tavatecan (IBI343) is an antibody-drug conjugate aimed at CLDN18.2, a protein found on many gastric cancers. IBI324 is a VEGF/ANG2 eye drug partnered with Ollin Biosciences. Innovent puts their combined addressable market above US$60 billion, a company estimate.

The odds

IBI363 is the biggest bet and still early in hard evidence. Long-term phase 1 data at ASCO showed median overall survival of 18.2 months at 3 mg/kg in squamous lung cancer that had stopped responding to immunotherapy, from a China-only study without a control arm. The global MarsLight-11 phase 3 now tests it against docetaxel in both squamous and non-squamous disease.

The BIO, Informa and QLS study found that 57.8% of phase 3 programs reach a filing and that only 7.9% of drugs entering phase 1 reach approval. Arcotatug tavatecan has an open-label phase 3 trial in China and Japan, G-HOPE-001, that met its primary endpoint at the first interim analysis, and the Chinese filing has priority review. An IBI363 investigator noted in the ASCO release that several large phase 3 trials in lung cancer after chemotherapy and immunotherapy have not yet delivered satisfactory outcomes.

The money

The finances are strong. First-half 2026 total revenue was RMB 8,617.8 million, up 44.8%, and product revenue rose 56.7% to RMB 8,201.5 million. IFRS profit rose 50.2% to RMB 1,253.1 million. Cash on hand was RMB 30.2 billion, about US$4.5 billion, as of July 31, 2026.

Partners add more. Innovent said deals signed over ten months with Takeda, Eli Lilly, Pfizer, Ollin and Spero have an aggregate potential value of about US$34 billion, most of it in milestones that may never be paid. The company targets RMB 35 billion to RMB 40 billion of revenue by 2030.

The risks

IBI363 has real toxicity at the dose being pushed forward. Grade 3 or worse treatment-emergent adverse events hit 64.9% of patients on 3 mg/kg, against 30.6% at lower doses. A global phase 3 against docetaxel will show whether the survival tail holds up under randomization.

Margins are slipping slightly as the mix widens: gross margin was 85.0% versus 86.0% a year earlier, while research spending rose to RMB 1,683.7 million from RMB 1,008.8 million. Outside China, Innovent shares control of its best assets with partners. Takeda holds ex-China rights to arcotatug tavatecan and co-develops IBI363.

Our read

Innovent has crossed into steady profit with fast growth and a large cash pile. The near-term story is execution in China: mazdutide, newly reimbursed drugs and a CLDN18.2 approval. The long-term story is whether IBI363 can win a global phase 3 in a setting where several large trials have not delivered. The ESMO gastric data and the first IBI363 melanoma readout, due by early 2027, are the next real tests.